Johnson & Johnson (JNJ)vsSoleno Therapeutics Inc (SLNO)
JNJ
Johnson & Johnson
$276.32
+3.81%
HEALTHCARE · Cap: $657.68B
SLNO
Soleno Therapeutics Inc
$53.01
0.00%
HEALTHCARE · Cap: $2.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 34753% more annual revenue ($99.33B vs $285.01M). SLNO leads profitability with a 33.7% profit margin vs 16.2%. SLNO trades at a lower P/E of 27.4x. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
SLNO
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-89.3%
Fair Value
$144.28
Current Price
$276.32
$132.04 premium
Intrinsic value data unavailable for SLNO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 33.6%
Every $100 of equity generates 26 in profit
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Moderate valuation
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : SLNO
The strongest argument for SLNO centers on Profit Margin, Operating Margin, Return on Equity. Profitability is solid with margins at 33.7% and operating margin at 33.6%.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : SLNO
The primary concerns for SLNO are P/E Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SLNO is a value play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.21 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 52/100), backed by strong 16.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Soleno Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?